What question did this study set out to answer?

This research aims to evaluate treatment patterns and outcomes related to first-line Bruton tyrosine kinase inhibitors in elderly patients with chronic lymphocytic leukemia.

February 13, 2026Expert Review of Hematology0 citations

View Full Paper

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia

SASikander Ailawadhi SCSwetha Challagulla PCPo-Ya Chuang

Key Points

This research aims to evaluate treatment patterns and outcomes related to first-line Bruton tyrosine kinase inhibitors in elderly patients with chronic lymphocytic leukemia.
Real-world study using patient data
Comparison between zanubrutinib, acalabrutinib, and ibrutinib
Assessment of time to treatment discontinuation (TTD)
Evaluation of healthcare resource utilization (HCRU)
Zanubrutinib showed longer time to treatment discontinuation (TTD) compared to acalabrutinib and ibrutinib.
Lower rates of treatment discontinuation were observed with zanubrutinib.
Zanubrutinib was associated with decreased healthcare resource utilization (HCRU).

Abstract

This real-world study demonstrated that zanubrutinib was associated with longer TTD, lower discontinuation rates, and less HCRU compared to acalabrutinib or ibrutinib in older CLL patients aged ≥65 years.

AIに質問

Bookmark

View Full Paper

AIに質問

Bookmark

View Full Paper

Real-world treatment utilization patterns, discontinuation and healthcare resource utilization of first-line Bruton tyrosine kinase inhibitors among elderly patients ≥65 years in chronic lymphocytic leukemia

Key Points

Abstract

Cite This Study